• 靶点：
• p21

• 简介：
• >>Endocrine resistance;>>Platinum drug resistance;>>ErbB signaling pathway;>>HIF-1 signaling pathway;>>FoxO signaling pathway;>>Cell cycle;>>p53 signaling pathway;>>PI3K-Akt signaling pathway;>>Cellular senescence;>>JAK-STAT signaling pathway;>>Oxytocin signaling pathway;>>Parathyroid hormone synthesis, secretion and action;>>Cushing syndrome;>>Hepatitis C;>>Hepatitis B;>>Human cytomegalovirus infection;>>Human papillomavirus infection;>>Human T-cell leukemia virus 1 infection;>>Kaposi sarcoma-associated herpesvirus infection;>>Epstein-Barr virus infection;>>Pathways in cancer;>>Transcriptional misregulation in cancer;>>Viral carcinogenesis;>>Proteoglycans in cancer;>>MicroRNAs in cancer;>>Colorectal cancer;>>Renal cell carcinoma;>>Pancreatic cancer;>>Endometrial cancer;>>Glioma;>>Prostate cancer;>>Thyroid cancer;>>Basal cell carcinoma;>>Melanoma;>>Bladder cancer;>>Chronic myeloid leukemia;>>Small cell lung cancer;>>Non-small cell lung cancer;>>Breast cancer;>>Hepatocellular carcinoma;

• 基因名称：
• CDKN1A

• 蛋白名称：
• Cyclin-dependent kinase inhibitor 1

• Human Gene Id：
• 1026

• Human Swiss Prot No：
• P38936

• Mouse Gene Id：
• 12575

• Mouse Swiss Prot No：
• P39689

• 免疫原：
• The antiserum was produced against synthesized peptide derived from human p21 Cip1. AA range:111-160

• 特异性：
• p21 Polyclonal Antibody detects endogenous levels of p21 protein.

• 组成：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• 来源：
• Polyclonal, Rabbit,IgG

• 稀释：
• IF 1:50-200 WB 1:500 - 1:2000. ELISA: 1:20000. Not yet tested in other applications.

• 纯化工艺：
• The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

• 浓度：
• 1 mg/ml

• 储存：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• 其他名称：
• CDKN1A;CAP20;CDKN1;CIP1;MDA6;PIC1;SDI1;WAF1;Cyclin-dependent kinase inhibitor 1;CDK-interacting protein 1;Melanoma differentiation-associated protein 6;MDA-6;p21;

• 实测条带：
• 21kD

• 背景：
• This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-cyclin-dependent kinase2 or -cyclin-dependent kinase4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen, a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of cyclin-dependent kinase2, and may be instrumental in the execution of apoptosis following caspase activation. Mice that lac

• 功能：
• function:May be the important intermediate by which p53 mediates its role as an inhibitor of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression.,induction:By p53, mezerein (antileukemic compound) and interferon beta.,PTM:Phosphorylation of Thr-145 by Akt or of Ser-146 by PKC impairs binding to PCNA.,similarity:Belongs to the CDI family.,tissue specificity:Expressed in all adult human tissues, with 5-fold lower levels observed in the brain.,

• 细胞定位：
• Cytoplasm . Nucleus .

• 组织表达：
• Expressed in all adult tissues, with 5-fold lower levels observed in the brain.

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs